Novel Approaches to Pain Therapy | Pharmacor | G7 | 2014
In 2013, total sales for pain therapies in the seven major pharmaceutical markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) were estimated to be $36.5 billion. Well-established opioid analgesics and NSAIDs dominate the current pain market, but they are fraught with safety and tolerability concerns and are not sufficiently effective in all patients—leaving substantial commercial opportunity for pain therapies that offer improvements over current therapeutic options, in particular products that feature novel mechanisms of action. In this report we provide detailed analysis on emerging analgesic therapies that represent 13 new drug classes; these agents were individually selected from hundreds of development programs based on their clinical promise according to interviewed experts and their market potential over the next 15 years.
